Remove Diabetes Remove Immunization Remove Presentation
article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

article thumbnail

Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?

Pharmaceutical Technology

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Retatrutide Overview Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus and obesity. million in FY2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

article thumbnail

Developing a new treatment paradigm for IgAN

European Pharmaceutical Review

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.

article thumbnail

Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?

Pharmaceutical Technology

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab? appeared first on Pharmaceutical Technology.

article thumbnail

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

article thumbnail

Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Pharmacy Times

SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Results and conclusions will be shared during the OPC presentation. Conclusions Conclusions are pending and will be presented at the OPC meeting in Austin, Texas, from June 19 to 20, 2025.

26